| 发明名称 | Treatment of immunocompromised conditions | ||
| 摘要 | This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division. | ||
| 申请公布号 | US9486497(B2) | 申请公布日期 | 2016.11.08 |
| 申请号 | US200812746894 | 申请日期 | 2008.11.07 |
| 申请人 | THE UNIVERSITY OF QUEENSLAND | 发明人 | Levesque Jean-Pierre;Winkler Ingrid |
| 分类号 | A61K45/06;A61K31/00;A61K38/17;A61K31/7004;A61K31/7016;A61K31/702;A61K31/7032;A61K31/7056;A61K38/19;A61K31/675;A61K31/70;A61K47/48;C07K14/705;C07K7/00;C07K7/06;C07K7/08;C07K16/28;C07K14/54;C07K14/475;A61K38/04;A61K38/08;A61K38/10;A61K38/18;A61K39/395;A61K39/00 | 主分类号 | A61K45/06 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP |
| 主权项 | 1. A method for treating an immunocompromised condition in a subject, which condition results from a medical treatment comprising chemotherapy or radiation therapy, the method comprising administering to the subject an E-selectin antagonist in an effective amount to treat the immunocompromised condition, wherein the subject is not exposed to an ancillary treatment that comprises transplantation of hematopoietic stem cells (HSC), other than autologous HSC, and wherein the E-selectin antagonist binds to E-selectin. | ||
| 地址 | Queensland AU | ||